EGFR and neoplasm: In prior studies, patients with left-sided tumours receiving chemotherapy plus an anti-EGFR antibody have demonstrated superior treatment outcomes in terms of PFS, OS, and ORR compared with patients with right-sided tumours receiving the same therapy [4, 9].